This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Top Stock Reports for Facebook, Netflix & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).
3 Top Lessons Learned from Buffett's 2020 Portfolio Moves
by Tracey Ryniec
During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
by Zacks Equity Research
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
3 Top Lessons Learned from Buffett's 2020 Portfolio Moves
by Tracey Ryniec
During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
by Zacks Equity Research
Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.
The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair
Is AbbVie (ABBV) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
Top Analyst Reports for AbbVie, Square & Honda Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Square, Inc. (SQ) and Honda Motor Co., Ltd. (HMC).
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.
Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus
by Zacks Equity Research
Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.
Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.
AbbVie (ABBV) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
Company News for Nov 2, 2020
by Zacks Equity Research
Companies In The News Are: ABBV, HON, CVX, RCL
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.